New US patent approval for Episurf Medical

Report this content

Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the United States Patent and Trademark Office (USPTO). The patent, entitled “System, guide tools and design methods related thereto for performing osteochondral transplantation surgery in a joint”, is within the area of devices and processes to facilitate treatment of joint lesions with osteochondral grafts.

“This is a patent that shows how the company’s medical imaging technology can be applied to a broader range of devices than the Episealer® joint implants. 3D modelling, damage visualisation and individualised design here form the basis for a guide system developed for osteochondral transfer such as for example autograft and allograft surgery”, says Katarina Flodström, COO, Episurf Medical.  

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website:

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.15 CET on 25 March 2020.